8 results about "Erg" patented technology

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The invention belongs to the technical field of biomedical instruments, and particularly relates to a device for detecting and intervening fundus retinopathy, which comprises an external energy transmitting device and a multifunctional integrated flexible corneal contact lens, and is characterized in that energy is provided for a biological light adjusting unit in the multifunctional integrated flexible corneal contact lens through the external energy transmitting device; according to the multifunctional integrated flexible corneal contact lens, the LED patch is integrated, and non-invasive intervention and treatment on the retina are achieved through the biological light adjusting technology. The receiving coil and the ERG electrode adopt a parting paper-cut structural design, so that the tensile property of the ERG electrode and the overall flexibility and structural consistency of the device are improved. The closed-loop management of'detection-treatment 'of retinal diseases is successfully realized, the device has more excellent histocompatibility, wearing comfort and large-scale production feasibility, and an innovative solution is provided for diagnosis and treatment of fundus diseases.

The invention discloses an SLO, SS-OCT and ERG synchronous ophthalmology multimodal imaging system, and belongs to the field of medical imaging equipment. The system comprises an SLO module, an SS-OCT module, an ERG module, an FPGA main control board and an image processing unit. The FPGA main control board generates a unified hardware clock and a global synchronous trigger signal, controls the three modules to work synchronously based on the same time reference, and adds a unified timestamp to all collected data. And the image processing unit realizes spatial positioning of SS-OCT fault data in an SLO image coordinate system and time sequence alignment of an ERG electrophysiological signal and an SS-OCT scanning position on the basis of the timestamp and a coordinate mapping relation between the SLO and the SS-OCT. According to the method, through hardware-level synchronization and accurate registration, the problem of space-time non-uniformity of multi-modal data is solved, point-to-point fusion of retina structure and function information is realized, and the early diagnosis and evaluation capability of ophthalmic diseases is remarkably improved.

This invention discloses the use of arginine polyesteramide in the preparation of drugs for treating dry age-related macular degeneration (AMD). This invention is the first to discover that arginine polyesteramide 2A6S can be used to prevent and treat dry age-related macular degeneration (AMD). Specifically, 2A6S can effectively restore ERG amplitude in patients with dry AMD, reduce fundus pathological damage and maintain the integrity of the retinopathy of prematurity (RPE), and reduce the expression of inflammatory factors by inhibiting the NF-κB pathway. Its efficacy is superior to existing complement C3 inhibitory peptides and NF-κB signaling pathway inhibitors, and it has potential clinical application value for dry AMD, contributing to the expansion of treatment strategies for dry AMD.

The application relates to the technical field of biological medicine, and particularly discloses a bifunctional fusion protein and application thereof in treating retinal degenerative diseases. The fusion protein is named Beva-1L, which is formed by fusing an amino acid sequence of human brain-derived neurotrophic factor (BDNF) with a light chain of an anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab. The fusion protein can simultaneously inhibit VEGF-mediated pathological angiogenesis and provide neurotrophic support, and is used for treating retinal degenerative diseases such as diseases simulated by an rd10 mouse model. Experiments show that the amplitude of a retinal electrogram (ERG) of the rd10 mouse can be significantly improved by injecting the Beva-1L, and the effect is equivalent to that of a positive drug. The application also relates to a coding gene, an expression vector, a host cell, a pharmaceutical composition of the fusion protein and application thereof. The fusion protein has a bifunctional synergistic effect, and provides a new treatment strategy for retinal degenerative diseases.

An apparatus for obtaining a retinal ERG signal from a target region of a retina, the apparatus comprising equipment for obtaining an electrical response signal from the target region and at least one light source configured to provide at least a stimulus light beam and a light-adapting background light beam, the stimulus light beam being configured to illuminate the target region to evoke the ERG signal, the light-adapting background light beam being configured to illuminate the retina at least in a region outside the target region for light-adapting the region outside the target region and suppressing the ERG signal transmitted from the region outside the target region.

Provided herein are compositions and methods for preventing ocular vascular regression, preserving visual function, or both, comprising: identifying a subject in need of treatment for ocular vascular regression; and providing the subject with an effective amount of an agent that is: an agonist that increases expression of at least one gene selected from: ETS-Related Gene (ERG), Fli-1 Proto-Oncogene; ETS Transcription Factor (FLU); KEF transcription factor 2 (KLF2); KEF transcription factor 4 (KLF4); or a Piezo-Type Mechanosensitive Ion Channel Component 1 (PIEZO1) agonist, or both; wherein the agent is provided in an amount sufficient to prevent the ocular vascular regression, preserving visual function, or both.